Seattle and Vienna, January 20, 2026 — Parse Biosciences and Graph Therapeutics have announced a strategic partnership to create one of the largest and most comprehensive functional immune perturbation atlases ever assembled. By combining AI-driven experimental design with industrial-scale single-cell transcriptomics, the collaboration aims to profile hundreds of millions of patient-derived immune cells under systematic perturbation, transforming how immune dysfunction is understood and how drug discovery and development are executed in immune-mediated diseases.
Science Significance
Scientifically, the partnership addresses one of immunology’s most persistent challenges: the extreme context- and patient-specific variability of immune cell behavior. Autoimmune and inflammatory diseases are driven by dynamic interactions among diverse immune and tissue cell populations, making static or simplified models insufficient. By integrating Graph’s lab-in-the-loop, active learning platform with Parse’s GigaLab powered by Evercode™ single-cell technology, the collaborators will generate high-resolution, whole-transcriptome datasets at unprecedented scale. This approach allows researchers to systematically perturb patient-derived immune cells, observe functional responses across disease contexts, and map causal immune pathways with a depth and breadth not previously achievable.
Regulatory Significance
From a regulatory science perspective, the initiative supports the growing emphasis on mechanistically informed, human-relevant data in early drug development. Regulators increasingly expect evidence that therapeutic hypotheses are grounded in biologically meaningful human models, particularly for complex immune diseases where animal models often fail to translate. The immune perturbation atlas provides a foundation for better target validation, biomarker discovery, and rational dose selection, potentially reducing late-stage clinical failures. Over time, such data-rich platforms may contribute to more predictable development programs, aligning with regulatory goals of improving clinical success rates and patient safety.
Business Significance
Advertisement
Commercially, the collaboration positions both companies at the forefront of AI-enabled drug discovery infrastructure. For Graph Therapeutics, the atlas strengthens its next-generation inflammation and immunology platform, enabling faster hypothesis testing and more confident prioritization of drug programs. For Parse Biosciences, the partnership showcases the scalability and industrial relevance of its single-cell sequencing ecosystem, reinforcing its role as a foundational data generator for large biopharma and biotech partners. By preventing costly late-stage failures, the approach has the potential to save millions of dollars per drug program, fundamentally improving the economics of immune disease drug development.
Patients’ Significance
For patients with autoimmune and immune-mediated diseases, the implications are substantial. Many such conditions lack curative therapies, in part because heterogeneous immune responses make it difficult to predict who will benefit from a given drug. By revealing how specific immune cell states and interactions drive disease in real patient samples, the atlas can accelerate the discovery of more precise, durable, and personalized treatments. Over time, this could translate into higher clinical trial success rates, faster access to innovative medicines, and therapies that are better matched to individual patient biology.
Policy Significance
At a policy level, the partnership aligns with broader priorities to modernize biomedical research through data-driven, human-centric approaches. Governments and funding bodies are increasingly supporting AI, big data, and advanced biological platforms that can de-risk innovation and improve public health outcomes. Large-scale immune atlases built from patient-derived cells support policies aimed at reducing R&D inefficiency, encouraging responsible AI adoption, and strengthening translational science ecosystems. Such initiatives also reinforce the importance of data as strategic infrastructure rather than a byproduct of experimentation.
The collaboration between Parse Biosciences and Graph Therapeutics represents a significant step toward redefining immune drug discovery. By uniting AI-guided experimentation with massive single-cell profiling, the partners are creating a living, functional map of immune dysfunction that could reshape how therapies for autoimmune and inflammatory diseases are discovered and developed. As the immune perturbation atlas grows, it promises to compress development timelines, reduce biological uncertainty, and ultimately improve outcomes for patients, signaling a new era in AI-first, data-intensive biomedical innovation.
Source: Parse Biosciences, Graph Therapeutics press release
